Revolution Medicines – A Market Analysis

Revolution Medicines stock is trading -6.85% below its average target price of $47.0 after marking a 10.6% during today's afternoon session. Analysts are giving the Mid-Cap Biotechnology company an average rating of buy and target prices ranging from $40.0 to $63.0 per share.

Revolution Medicines has an average level of shares sold short, at 10.0% of its total share float. The stock's short ratio (also called days to cover) is 13.5. Since 2.39% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.

Institutional investors own 98.9% of Revolution Medicines's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Revolution Medicines

Date Reported Holder Percentage Shares Value
2024-03-31 Vanguard Group Inc 9% 14,757,112 $646,066,345
2024-03-31 Wellington Management Group, LLP 9% 14,714,726 $644,210,686
2024-03-31 Blackrock Inc. 7% 12,308,002 $538,844,312
2024-03-31 Baker Brothers Advisors, LLC 5% 7,549,249 $330,506,112
2024-03-31 Farallon Capital Management LLC 5% 7,507,872 $328,694,626
2024-03-31 Nextech Invest Ag 4% 6,296,740 $275,671,269
2024-03-31 BVF Inc. 4% 5,981,212 $261,857,454
2024-03-31 Casdin Capital, LLC 3% 5,617,599 $245,938,477
2024-03-31 State Street Corporation 3% 5,386,020 $235,799,949
2024-03-31 Alphabet Inc. 3% 5,301,512 $232,100,188
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.